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Abstract
Background: Advances in natural language processing and other machine learning techniques have led to the development of
automated agents (chatbots) that mimic human conversation. These systems have mainly been used in commercial settings, and
within medicine, for symptom checking and psychotherapy. The aim of this systematic review was to determine the acceptability
and implementation success of chatbots in the follow-up of patients who have undergone a physical healthcare intervention.
Methods: A systematic review of MEDLINE, MEDLINE In-process, EMBASE, PsychINFO, CINAHL, CENTRAL and the grey literature
using a PRISMA-compliant methodology up to September 2020 was conducted. Abstract screening and data extraction were
performed in duplicate. Risk of bias and quality assessments were performed for each study.
Results: The search identified 904 studies of which 10 met full inclusion criteria: three randomised control trials, one
non-randomised clinical trial and six cohort studies. Chatbots were used for monitoring after the management of cancer,
hypertension and asthma, orthopaedic intervention, ureteroscopy and intervention for varicose veins. All chatbots were deployed on
mobile devices. A number of metrics were identified and ranged from a 31 per cent chatbot engagement rate to a 97 per cent response
rate for system-generated questions. No study examined patient safety.
Conclusion: A range of chatbot builds and uses was identified. Further investigation of acceptability, efficacy and mechanistic
evaluation in outpatient care pathways may lend support to implementation in routine clinical care.
Introduction
The first known agent capable of conversation between human
and machine was developed in 19661. Eliza used early natural lan-
guage processing to return open-ended questions to users, simu-
lating person-centred psychotherapy.
Developments in speech recognition, natural language proc-
essing, natural language understanding and artificial intelligence
have led to the design of systems capable of mimicking human
interaction with unconstrained natural language input2. A chat-
bot is defined as ‘a computer program designed to simulate con-
versation with human users, particularly over the internet’3. A
recent systematic review involving 17 studies and 1573 partici-
pants found that chatbots in healthcare were predominantly
used in mental health conditions to educate patients and collect
data from health-related questionnaires4.
Financial pressures and clinical demand have driven interest
in virtual clinics for monitoring and surveillance following
healthcare interventions5, particularly during the COVID-19 pan-
demic, with rapid adoption of virtual services to moderate
infection risk through reduction of direct clinician–patient con-
tact6. A recent randomised trial involving 209 general surgical
patients demonstrated better attendance (92 versus 81 per cent)
and higher patient satisfaction (95 per cent of participants happy
or very happy versus 56 per cent) with virtual postoperative clinics
compared with traditional outpatient follow-up7.
Chatbots hold promise in increasing the efficiency of outpatient
care pathways and meeting the need for patient surveillance and
education between face-to-face clinic appointments. Accuracy of
information and patient safety, however, are important considera-
tions. The aim of this systematic review was to determine the up-
take, acceptability and utility of chatbots in the follow-up of
patients who have received physical healthcare interventions.
Methods
The systematic review was designed and reported in accordance
with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement8. The protocol was
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prospectively registered in the PROSPERO database (registration
number: CRD42020199919)9.
Search strategy
Search strategies included free text and index terms related to
the following core concepts: ‘chatbot’ ‘intervention’ and ‘follow-
up’ (Fig. S1, supplementary material). The following databases
were searched from inception until 18 September 2020:
MEDLINE, MEDLINE In Process, EMBASE, Cochrane CENTRAL,
CINAHL and PsychINFO. The Central database was searched for
registered clinical trials up until 9 November 2020. The search
was not restricted by language or date of publication. A further
search of the surgical grey literature was conducted by examin-
ing the proceedings of the 2020 Association of Surgeons in
Training International Surgical Conference10,11.
Eligibility criteria
All studies reporting original data were eligible for inclusion, in-
cluding randomised trials, quasi-experimental designs, cohort
studies, case-control studies and case series. Case reports,
reviews, meta-analyses and articles related to the technical de-
velopment of systems without accompanying clinical data were
excluded. Systematic reviews were screened for potentially eligi-
ble publications. The titles and abstracts of identified articles
were independently screened by two authors.
Participants
Adult and paediatric patients who had undergone any physical
healthcare intervention targeting physical rather than mental
health and who were subsequently followed up using an auto-
mated conversational agent (a chatbot) at any point after an in-
tervention were eligible for inclusion. Physical interventions were
defined as procedures where purposeful access to the body was
gained via an incision, percutaneous puncture or instrumenta-
tion via a natural orifice or the provision of medications to treat
underlying disease. Examples of physical interventions included
total hip replacement for osteoarthritis, steroid injection for car-
pal tunnel syndrome, transurethral resection of the prostate for
benign prostatic hyperplasia and the prescription of antihyper-
tensive medication.
Interventions and comparators
A chatbot was defined as a computer software application that
permits two-way conversation (via text, speech or a combination
of both) between a human user and a computer program3.
Comparators included other automated or non-automated fol-
low-up systems, including, for example, routine care delivered
via face-to-face outpatient clinics and follow-up telephone calls.
Outcomes
The primary outcome assessed was the acceptability of chatbots
as a method of follow-up indicated by implementation success.
Measures of acceptability included user engagement (defined as
the proportion of patients who activated and interacted with the
chatbot), patient adherence to the chatbot, response rate (defined
as the proportion of patients responding to system queries), dura-
tion of adherence and interactions with the chatbot over time.
Patient safety and accuracy statistics were assessed where
reported. Additional outcomes assessed included patient cohort
demographics, design features such as task orientation, dialogue
management, input and output formats, platforms used, health
questionnaires used and measures of patient satisfaction.
Study selection
Potentially eligible studies were compiled, and duplicate citations
removed. Two authors independently screened titles and
abstracts of retrieved studies using prespecified stepwise inclu-
sion/exclusion criteria. Disagreements between reviewers were
resolved through consultation with a third reviewer. Reference
lists of included studies and published narrative/systematic
reviews were examined for further potentially eligible studies.
Data extraction and analysis
Data were extracted using a predefined electronic data-collection
form. Extracted data were collated, cross-checked by other
authors and compared. Study setting, population demographics,
healthcare interventions, cohort-specific factors, software design
features, measures of adherence, patient experience and clinical
outcomes were extracted. Formal meta-analysis was not per-
formed due to heterogeneous outcome reporting and differences
in study designs. A narrative synthesis and descriptive analysis
were used.
Risk of bias analysis
Methodological quality of each included study was assessed. For
randomised trials, this involved the revised Cochrane Risk of Bias
tool12, and for non-randomised comparative studies the
Cochrane Risk of Bias in non-randomised studies of interventions
(ROBINS-I) tool13. The National Institute of Health (NIH) quality
assessment tool for cohort studies was employed to assess the
quality of cohort studies14.
Results
From a total of 908 potential studies, 709 remained for screening
after removal of duplicates, of which 11 articles were finally
assessed with 10 meeting full inclusion criteria (Fig. 1).
Study characteristics
Three randomised control trials (RCTs) were identified. One in-
volving 76 participants compared an automated text-based chat-
bot with standard postoperative care following upper or lower
extremity fracture15. The second, involving 142 participants,
compared an automated chatbot versus physician-generated ad-
vice for women who had undergone breast cancer treatment16
and the third, with 45 participants, compared immediate versus
delayed access to a chatbot in young patients affected by various
cancers17.
The non-randomised comparative clinical study included 270
participants and compared an automated speech-based chatbot
to manual telephone follow-up for patients who had undergone
orthopaedic surgery18. The remaining six studies19–24 were cohort
studies based on an established definition25. Collectively, eight
out of 10 studies were published between 2019 to 2020.
Demographics
Of the 10 included studies, nine recruited adults, and one adoles-
cents with a mean age of 15 years19 (Table 1) resulting in a total of
5492 patients. Chatbots were used to follow up patients after
elective orthopaedic surgery18, orthopaedic trauma surgery15,
surgical intervention for varicose veins21, women treated for
breast cancer16,24, uretoscopy23 as well as the medical manage-
ment of hypertension20, asthma19 and various cancers17,22.
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Quality of included studies
One RCT was deemed to have a high risk of bias due to ascertain-
ment bias and risk of detection bias given the effect of unblinding
on the outcome of interest17. The remaining two RCTs were
deemed at moderate risk of conduct bias15,16.
The cohort studies were rated as fair19,22,23 or poor quality20
(Fig. S2a–c, supplementary material). The quality of outcome
measurement and assessment was deemed poor across all co-
hort studies.
Interventions
All studies deployed chatbots on mobile devices: two were also
accessible via web-based applications16,24 and one was accessible
via Facebook Messenger17. In terms of chatbot construct, seven
used a frame-based knowledge-representation system16–20,23,24,
one used a rule-based knowledge-representation system22 and
two studies did not report the type of system used15,21. Of the 10
studies, three used a system-focused dialogue15,22,23, two a user-
focused dialogue16,24 and the other five used a mixed dialogue
initiative17–21. Task orientation was reported in two studies, one
chatbot was able to book follow-up appointments21 and one was
able to input patient data into electronic medical records20.
Outcomes
Measures of implementation success were reported in seven of
10 studies17–19,21–24. Adherence ranged from 31 per cent partici-
pant engagement rate24 to 97 per cent participant response rate
for select system-generated questions19. One study demonstrated
a decline in engagement from 100 to 31 per cent after 8 months
of chatbot use24. A comparative study demonstrated a 92 per
cent follow-up rate for patients contacted via an autonomous
postoperative chatbot versus a 93 per cent follow-up rate for
patients contacted directly by phone18.
Other outcome measures reported by studies included pa-
tient-reported outcome scores (PROMs), patient feedback, patient
experience and technical details related to chatbot performance
(Table 2). One RCT demonstrated that a chatbot with twice-daily
text-based output for 2 weeks was associated with reduced opiate
consumption compared with a control cohort (no messages re-
ceived) following orthopaedic trauma surgery (26 opiate tablets
versus 41 tablets)15. Another RCT found no differences in per-
ceived quality of responses using the between chatbot versus
real-time physician-written responses to user queries from
women treated for breast cancer (average QLQ-INFO25 score 2.89
and 2.82 respectively)16. The third RCT reported no significant dif-
ference in symptoms of anxiety and depression, quantified using
the Emotional Disturbance Anxiety Score, between patients using
a chatbot (cohort 1) and a control cohort without chatbot access
(cohort 2) over a 4-week study period. Upon completion of the
first study period, the control cohort (cohort 2) were then granted
access to the chatbot and symptoms of anxiety and depression
were quantified after a second 4-week study period. After the sec-
ond study period, patients in cohort 2 demonstrated a reduction
in reported symptoms of anxiety compared with baseline
measurements and anxiety scores after the first study period,
although this reduction was not statistically significant17. A non-
randomised comparative study demonstrated comparable
follow-up consultation rates after orthopaedic surgery using a
telephone-based conversational agent compared with calls made
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Fig. 1 PRISMA flow diagram
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Registered trials
The authors’ search found two additional registered protocols for
ongoing clinical trials. Study protocols outline the intended use
of chatbots to facilitate questionnaire completion at 6 and 8
months following bariatric surgery26 and for daily consultation
with patients treated for Parkinson’s disease27 (Fig. S3, supple-
mentary material).
Discussion
The use of chatbots following a physical healthcare intervention
is a new and evolving field, with eight of 10 studies published dur-
ing or after 2019. It seems likely that this will continue to in-
crease, with a move towards efficiency in healthcare systems and
a move away from face-to-face follow-up arising from the
COVID-19 pandemic.
A review investigating the broader use of conversational
agents in healthcare has been published4, while the present re-
view was focused on the role of technology after interventions.
The systematic review identified 10 studies of different designs,
mostly of moderate to poor quality. All outcome measures were
inconsistently defined and outcome assessors were not blinded,
predisposing to detection bias and Hawthorne effect. One study
attempted to reduce this by blinding participants to responses
from either the chatbot or physicians16, although by the nature
of the intervention, a Hawthorne effect cannot be ignored.
Acceptability and patient experience using automated conver-
sational agents was largely positive19,21. There was no clinically
important difference in rates of patient satisfaction with chatbot
responses compared with real-time physician-generated
responses to user queries, measured using the QLQ-INFO2516.
Previous work has demonstrated the QLQ-INFO25 is acceptable
with good internal consistency and test–retest reliability28. The
reduction in opiate prescribing, time and cost saving reported in
one small study provides useful evidence supporting investment
in automated follow-up systems15.
Despite the metrics used being heterogeneous, data around
success of implementation suggest considerable variation. Some
learning points were simple and applicable. One study described
a 35 per cent interaction rate with their chatbot, with the primary
reason for poor interaction being ‘misplacing instructions for
chatbot use’23, while another demonstrated an initial engage-
ment rate of 100 per cent at the start of the study that gradually
fell to 31 per cent over 8 months24, likely to represent reduced en-
thusiasm for patient engagement, although it might represent
patient adaptation to their current health state. Some support for
the latter is that most (88 per cent) participants reported that the
chatbot provided them with support and helped them follow
their treatment plan. A structured sequence to implementation
may increase success, and frameworks for this have been devel-
oped for the deployment of PROMs that might be applicable to
automated follow-up systems29.
No study identified in the current systematic review examined
patient safety. If autonomous agents are to be used in clinical
practice to monitor patient status actively after intervention, rig-
orous safety testing using simulated patients is warranted before
clinical adoption. Following implementation, prospective regis-
tries of technological adverse events should be kept. Here, tech-
nological adverse events refer to patient harm directly caused by
technology. This harm may be direct (inappropriate clinical ad-
vice) or indirect (failing to identify clinical signs of deterioration).
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on mobile devices. In the UK, 70 per cent of adults own a smart-
phone and over half regularly use applications30. Disparities in
socioeconomic status and technological literacy may limit access
to healthcare. Future epidemiological studies should seek to as-
certain whether clinical implementation of technologies nega-
tively impacts the health of certain cohorts within the
population.
The present study has a number of limitations. A small num-
ber of heterogeneous studies were identified, reporting a variety
of different adherence and clinical-outcome measures. The ma-
jority of studies were small, non-comparative feasibility studies.
The comparative studies were at risk of selection and detection
bias owing to the nature of interventions and relative infancy of
the field. Varying technical descriptions of agents were provided
and heterogeneity in outcome reporting precluded meaningful
meta-analysis, limiting the strength of conclusions that can
safely be drawn.
There is, nevertheless, early evidence of uptake of automated
conversational agents in the outpatient management of patients
following physical healthcare interventions. Despite a range of
chatbot builds and clinical uses, they seem to be generally ac-
ceptable, although effectiveness remains to be proven. Attention
to practical details around deployment may improve implemen-
tation success of future systems.
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